Deal overview
| Target | BLUEPRINT MEDICINES CORPORATION |
|---|---|
| Bidder | SANOFI SA |
| Price | £100.00 Full version or £25.00 Light version |
| Publication Date | Jun 02, 2025 |
| Abstract | On 2 June 2025, it was announced that Rothko Merger Sub, Inc. ("Rothko"), a subsidiary of the quoted French pharmaceutical company Sanofi SA ("Sanofi"), had entered into an agreement with the quoted US biopharmaceutical company Blueprint Medicines Corporation ("Blueprint") under which Rothko would acquire Blueprint for US$129.00 per share in cash at closing plus one ... |
| Number of pages (Full version) | 10 |
| Number of pages (Light version) | 2 |
| Format | Adobe Acrobat (Download Acrobat Reader) |
| Free Sample | Click Here to Download |
Purchase this report
Buy and download this report in a fast a safe way using our secure payment system. We accept all major credit cards.
©2025 M&A Monitor Limited
